Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406740 | 0.99 | NCF1 (0.53) | NCF1EGLN1MEN1KMT2AMAPT | |
| SCHEMBL5394892 | 0.88 | NCF1 (0.57) | NCF1MEN1KMT2AMAPTPTGS2 | |
| SCHEMBL5420552 | 0.86 | NCF1 (0.50) | NCF1EGLN1MEN1KMT2AMAPT | |
| SCHEMBL5397608 | 0.84 | SIRT2 (0.48) | NCF1MEN1KMT2AMAPT | |
| SCHEMBL5412918 | 0.84 | MEN1 (0.57) | NCF1MEN1KMT2AMAPTCDK2 | |
| SCHEMBL5401181 | 0.84 | NCF1 (0.74) | NCF1EGLN1MEN1KMT2AMAPT | |
| SCHEMBL27574129 | 0.83 | NCF1 (0.52) | NCF1EGLN1MEN1KMT2AMAPT | |
| SCHEMBL5397410 | 0.82 | NCF1 (0.72) | NCF1EGLN1MEN1KMT2AMAPT | |
| SCHEMBL27550363 | 0.81 | NCF1 (0.59) | NCF1EGLN1MEN1KMT2AMAPT | |
| SCHEMBL5518457 | 0.81 | NCF1 (0.62) | NCF1MEN1KMT2AMAPTNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | claimed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | claimed |
| US-7265125-B2 | Neuropeptide Y antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050176698-A1 | Neuropeptide Y antagonists | BREU VOLKER (DE) | 2005-08-11 | — | — | US | disclosed |
| US-6900226-B2 | Neuropeptide Y antagonists | HOFFMAN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20020052356-A1 | Neuropeptide Y antagonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176698-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | NCF1 1230/4885EGLN1 1248/4885MEN1 581/4885 |
| US-20020052356-A1 | Neuropeptide Y antagonists | NPY5R, NPY4R, NPY2R | NCF1 1230/4885EGLN1 1248/4885MEN1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.